SS
Steve Scala TD Cowen Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
AbbVie
ABBV
$372B
| $210.42 | $225 |
7%
upside
| Buy |
7 Oct ‘24
11 months ago |
|
2
Bristol-Myers Squibb
BMY
$96.1B
| $47.23 | $59 |
25%
upside
| Hold |
7 Oct ‘24
11 months ago |
|
3
AstraZeneca
AZN
$252B
| $81.22 | $95 |
17%
upside
| Buy |
12 Aug ‘24
1 year ago |
|
4
Merck
MRK
$211B
| $84.61 | $135 |
60%
upside
| Outperform |
4 Jan ‘24
1 year ago |
|
5
Pfizer
PFE
$140B
| $24.71 | $32 |
30%
upside
| Market Perform |
4 Jan ‘24
1 year ago |
|
6
Eli Lilly
LLY
$673B
| $750.61 | $500 |
33%
downside
| Outperform |
23 May ‘23
2 years ago |
|
7
Organon & Co
OGN
$2.7B
| $10.37 | $40 |
286%
upside
| Market Perform |
3 Jun ‘21
4 years ago |
|
8
Novartis
NVS
$248B
| $128.05 | $105 |
18%
downside
| Market Perform |
1 Feb ‘21
4 years ago |
|
9
Royalty Pharma
RPRX
$15.8B
| $36.50 | $55 |
51%
upside
| Outperform |
13 Jul ‘20
5 years ago |
|